Aquis Stock Exchange Weekly Highlights 14/10/24

Substrate Artificial Inteligence S.A. announced that it has successfully completed the delivery of a contract valued at €1.4m for the provision of 54 state-of-the-art ultrasound machines for the Health Service of the Principality of Asturias. Read more

ProBiotix Health Plc announced a Q3 2024 trading update (for the nine months to 30 September 2024) in which the Company highlighted that Sales increased by 39% to £1.5m (2023: £1.1m) and Gross Profit increased by 40% to £874,000 (2023: £623,000). Read more

The Company later announced a new commercial partnership with Mexico based raw materials and ingredients specialist Raff. Raff specialises in the use and application of lactic and probiotic cultures, rennet, enzymes and preservatives.

Steen Andersen, CEO, commented: "The cardiovascular drug market in Mexico is estimated to be worth $2.2 billion this year, and provides a huge latent opportunity. With an ageing population, we believe Mexico provides a highly attractive market for ProBiotix to target." Read more

SulNOx Group PLC announced that it has secured a further patent in the Kingdom of Saudi Arabia. This latest patent covers a range of formulation versions which includes both the Berol® 6446 Heavy Sulphur Fuel Oils emulsifiers and SulNOxEco™ Fuel Conditioners which enhance all diesel, petrol/gasoline and biofuels, and marine fuels. The Company says Saudi Arabia is an important new patent for SulNOx, representing validation in one of the world's largest and most influential oil producers. Read more

Ananda Developments Plc announced that it has signed a contract with Southern Star Research Pty Ltd, an Australian Contract Research Organisation, to carry out a Phase 1 clinical trial investigating the pharmacokinetic profile, tolerability and safety of the Company's lead investigative asset, MRX1.

Melissa Sturgess, CEO, commented: "This study represents a significant milestone in MRX1's journey to market, providing us with key data for MRX1's licensed drug development. Working with an excellent company such as Southern Star Research is a reflection of the high quality of work produced by the Ananda team. Southern Star Research's deep expertise in clinical research, particularly in the field of cannabinoids, will complement our own capabilities and accelerate the development of MRX1." Read more

🗓️ Event: The 3rd Aquis Showcase Event will be held at the Royal College of Surgeons, London on the 12th November 2024. Listen to 16 AQSE listed companies each delivering rapid fire pitches, all under 8-minutes. Secure your ticket now with 10% off using the code ‘SHS10’ here.🌟